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The amplified fragment length polymorphism technique has been applied to identify neurotropic chaeto-
thyrialean black yeasts and relatives from clinical sources. Cladophialophora bantiana, C. emmonsii, C. arxii, C.
devriesii, and C. modesta, previously identified on the basis of sequencing and phenotypic and physiological
criteria, were confirmed by cluster analysis, demonstrating the clear separation of C. bantiana as a rather
homogeneous group from the other species. C. bantiana is a neurotropic fungus causing cerebral abscesses with
a mortality of up to 70%. Successful therapy consists of neurosurgical intervention and optimal antifungal
therapy. Since the latter is not clearly defined in a large series, we tested the in vitro activities of eight antifungal
drugs against clinical isolates of C. bantiana (n  37), C. modesta (n  2), C. arxii (n  1), C. emmonsii (n 
1), and C. devriesii (n 1), all of which had caused invasive infections. The resulting MIC90s for all neurotropic
C. bantiana strains were as follows, in increasing order: posaconazole, 0.125 g/ml; itraconazole, 0.125 g/ml;
isavuconazole, 0.5 g/ml; amphotericin B, 1 g/ml; voriconazole, 2 g/ml; anidulafungin, 2 g/ml; caspofun-
gin, 4 g/ml; and fluconazole, 64 g/ml. On the basis of these in vitro results and the findings of previous
clinical and animal studies, posaconazole seems to be a good alternative to the standard treatment, ampho-
tericin B, for C. bantiana cerebral infections. The new agent isavuconazole, which is also available as an
intravenous preparation, has adequate activity against C. bantiana.
The genus Cladophialophora represents anamorph members
of the ascomycetes in the order Chaetothyriales in the family
Herpotrichiellaceae comprising the black yeasts and relatives
(10). These dematiaceous fungi are normally associated with
soil or vegetative matter; however, they are increasingly being
seen as causative agents of mycoses in humans (27, 37, 48) and
domestic (14, 23) and wild (29) animals. Cladophialophora
carrionii is the type species and an agent of chromoblasto-
mycosis, a cutaneous and subcutaneous disease. The genus
Cladophialophora encompasses several other clinically signifi-
cant species which are potentially able to cause severe fungal
infections in otherwise immunocompetent patients. In human
infections, the brain is frequently involved (27, 37, 48). Within
the genus, the majority of brain abscesses with fatal outcomes
are associated with Cladophialophora bantiana (formerly Cla-
dosporium bantianum, Cladosporium trichoides, Cladosporium
trichoides var. chlamydosporum, Torula bantiana, and Xylohy-
pha bantiana), a neurotropic fungus, although severe phaeohy-
phomycotic infections are also caused by novel Cladophialo-
phora species like C. modesta (40, 44), C. arxii (53, 56), C.
emmonsii (Xylohypha emmonsii) (45), C. devriesii (22, 28, 42) C.
saturnica (4), and C. boppii (34). Moreover, Exophiala derma-
titidis and Rhinocladiella mackenziei, other members of the
black yeast group, are also frequently isolated from cerebral
infections (8, 27, 37). Central nervous system infection due to
C. bantiana is reported worldwide, though a general prefer-
ence for warmer climates with high humidity is apparent (27).
Indeed, many cases are reported from India (19, 30, 33, 55), as
opposed to arid climatic zones (8). The first case of C. bantiana
(Cladosporium trichoides) infection was reported in 1952, when
the fungus was isolated from a human brain abscess and was
demonstrated to be neurotropic in laboratory animals (6). A
review of 17 cases of brain abscess, published in the English
language literature by the mid-1970s, reported that the major-
ity of patients had no underlying disease (41). The most recent
series of 48 patients with brain abscess due to C. bantiana
showed that 35 patients (72%) had no risk factors and that only
13 patients (28%) survived the infection, despite combined
surgical and antifungal treatment (48). The minority of immu-
nocompromised patients are transplant recipients, intravenous
drug abusers, or individuals on steroids (2, 13, 15, 24, 31, 35, 36,
51, 54, 57, 59).
The mode of infection is either by hematogenous spread
from an unrecognized pulmonary focus, through direct ex-
tension from adjacent paranasal sinuses, or by penetrating
trauma to the head. However, the majority of patients had
had no recent evidence of pulmonary or sinus infections
(27). Cladophialophora species are prone to identification
problems (3, 20). Due to the high degree of phenotypic simi-
larity between recently described new Cladophialophora spe-
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cies and C. bantiana, identification problems are imminent.
For most cases published in the older literature, identification
down to the species level cannot be repeated or confirmed by
molecular methods due to the absence of the original isolates;
hence, the etiological agent described in older publications
may often have been misidentified. It is now well established
that molecular identification methods, which have driven new
developments in fungal taxonomy, are more reliable than clas-
sical morphological methods (3, 20). Amplified fragment
length polymorphism (AFLP) is a technique based on the
detection of genomic restriction fragments by PCR amplifica-
tion, which can be used with the DNA of any organism (58).
The purpose of this study was to study the inter- and intraspe-
cific genomic variations of 42 Cladophialophora isolates stored
in the CBS collection and recovered from cases with cerebral
phaeohyphomycosis and other infections. Antifungal therapy is
mainly based on the experience gathered from and published
in isolated case reports and mostly involved amphotericin B,
itraconazole, and flucytosine singly or in different combina-
tions (48). Animal studies (1) and human experience suggested
that amphotericin B has no value in treating cerebral infec-
tions, probably due to poor penetration of the central nervous
system (CNS), but that triazoles might be of value (26, 38). A
recent study of antifungal therapy in a murine model of dis-
seminated infection by C. bantiana confirmed the poor activity
of amphotericin B but found that posaconazole and flucytosine
extended survival (39). This suggests that new antifungal drugs
with broad-spectrum activity and suitable pharmacokinetic
profiles compared with those of conventional antifungal agents
might be more effective against C. bantiana (1, 39). Only lim-
ited data on in vitro antifungal activities against the neurotropic
fungus C. bantiana are available. Therefore, with no standard
therapy available, unfavorable results in animal experiments,
and only a small published series of susceptibility testing with
itraconazole and voriconazole (47), the second objective of this
study was in vitro testing of this large collection of Cladophialo-
phora strains for their susceptibilities to eight antifungal
drugs, including the new triazole isavuconazole.
(Part of this work was presented as a poster at Trends in
Medical Mycology, Athens, Greece, October 2009 [4a].)
MATERIALS AND METHODS
Fungal strains. Table 1 summarizes the data for and characterizes a total of 42
isolates of Cladophialophora spp. that originated from different human and
veterinary clinical sources with cerebral phaeohyphomycosis or other infections.
Strains were obtained from the reference collection of the CBS-KNAW Fungal
Biodiversity Centre, Utrecht, Netherlands, and were handled under biosafety
level 3 conditions. Stock cultures for transient working collections were
initially grown on oatmeal agar (OA; Difco Oatmeal; Brunschwig Chemie,
Amsterdam, Netherlands) at 24°C for 1 week, and the organisms were iden-
tified to the species level by sequencing of the internal transcribed spacer
regions of the rDNA region and partial translation of the elongation factor
1-alpha and beta-tubulin genes (3).
DNA extraction. The fungal mycelia were grown on 2% malt extract agar
plates for 2 weeks at 24°C. A sterile blade was used to scrape the mycelium from
the surface of the plate. DNA was extracted using an Ultra Clean microbial DNA
isolation kit (Mobio, Carlsbad, CA), according to the manufacturer’s instruc-
tions. DNA extracts were stored at 20°C prior to use.
AFLP analysis. Approximately 50 ng of genomic DNA was subjected to a
combined restriction ligation procedure containing 50 pmol of HpyCH4 IV
adapter, 50 pmol MseI adapter, 2 U of HpyCH4 IV (New England Biolabs,
Beverly, MA), 2 U of MseI (New England Biolabs), and 1 U of T4 DNA ligase
(Promega, Leiden, Netherlands) in a total volume of 20 l of 1 reaction buffer
for 1 h at 20°C. Next, the mixture was diluted five times with 10 mM Tris-HCl
(pH 8.3) buffer. Adapters were made by mixing equimolar amounts of comple-
mentary oligonucleotides (5-CTCGTAGACTGCGTACC-3 and 5-CGGGTA
CGCAGTC-3 for HpyCH4 IV; 5-GACGATGAGTCCTGAC-3 and 5-TAG
TCAGGACTCAT-3 for MseI), heating to 95°C, and subsequently cooling
slowly to ambient temperature. One microliter of the diluted restriction-ligation
mixture was used for amplification in a volume of 25 l under the following
conditions: 1 M HpyCH4 IV primer with one selective residue (underlined)
(5-fluophore-GTAGACTGCGTACCCGTC-3), 1 M MseI primer with four
selective residues (underlined) (5-GATGAGTCCTGACTAATGAG-3), 0.2
mM each deoxynucleoside triphosphate, and 1 U of Taq DNA polymerase
(Roche Diagnostics, Almere, Netherlands) in 1 reaction buffer containing 1.5
mM MgCl2. Amplification was done as follows. After an initial denaturation step
for 4 min at 94°C in the first 20 cycles, a touchdown procedure was applied: 15 s
of denaturation at 94°C, 15 s of annealing at 66°C with the temperature for each
successive cycle lowered by 0.5°C, and 1 min of extension at 72°C. Cycling was
then continued for a further 30 cycles at an annealing temperature of 56°C. After
completion of the cycles, incubation at 72°C for 10 min was performed before the
reaction mixtures were cooled to room temperature. The amplicons were then
combined with an ET400-R size standard (GE Healthcare, Diegem, Belgium)
and analyzed on a MegaBACE 500 automated DNA platform (GE Healthcare),
according to the manufacturer’s instructions.
Data analysis. Data were inspected visually and were also imported into
BioNumerics (version 5.1) software (Applied Maths, Sint-Martens-Latem, Bel-
gium) and analyzed by the unweighted-pair group method using average linkages
(UPGMA) clustering using the Pearson correlation coefficient. The analysis was
restricted to DNA fragments in the range from 80 to 250 bp.
In vitro antifungal susceptibility testing. Amphotericin B (AMB; Bristol-
Myers-Squib, Woerden, Netherlands), fluconazole (FLU; Pfizer Central Re-
search Sandwich, United Kingdom), itraconazole (ITR; Janssen Research Foun-
dation, Beerse, Belgium), voriconazole (VOR; Pfizer), posaconazole (POS;
Schering-Plough, Kenilworth, NJ), isavuconazole (ISA; Basilea Pharmaceuticals,
Switzerland), caspofungin (CAS; Merck Sharp & Dohme BV, Haarlem, Neth-
erlands), and anidulafungin (ANI; Pfizer) were obtained from the manufacturers
as pure powders. As described in the Clinical and Laboratory Standards Institute
(CLSI) M38-A2 guidelines for in vitro susceptibility studies, additive drug dilu-
tions were prepared at 100 times the final concentrations in different solutions
(9). The drugs were diluted in standard RPMI 1640 medium (Sigma Chemical)
buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) buffer
(Sigma) with L-glutamine without bicarbonate to yield the following concentra-
tions: amphotericin B, itraconazole, voriconazole, posaconazole, and caspofun-
gin, 0.016 to 16 g/ml; fluconazole, 0.063 to 64 g/ml; and isavuconazole and
anidulafungin, 0.008 to 8 g/ml. The plates were stored at 70°C until they were
used. Broth microdilution was performed as described by the CLSI, in accor-
dance with the guidelines in document M38-A2 (9). Briefly, all clinical isolates
were grown on potato dextrose agar plates (PDA; Difco) at 35°C for up to 7 days
for sporulation. Inoculum suspensions were prepared under biosafety laboratory
level 3 regulations by slightly scraping the surface of mature colonies with a loop
in sterile saline solution with Tween 40 (0.05%). After the heavy particles were
allowed to settle, the homogeneous conidial suspensions were transferred to
sterile tubes and adjusted spectrophotometrically at a 530-nm wavelength to
optical densities (ODs) that ranged from 0.17 to 0.15 (68 to 71% transmission).
The inoculum suspensions, including mostly nongerminated conidia, were di-
luted 1:50 in RPMI 1640 medium. The final concentration of the stock inoculum
suspensions of the tested isolates ranged from 0.5  104 to 3.1  104 CFU/ml, as
determined by the use of quantitative colony counts to determine the viable
numbers of CFU per milliliter. After inoculation, the microdilution plates were
incubated at 35°C and examined visually and spectrophotometrically at 420 nm
after 72 h of incubation. The MIC endpoints were defined with the aid of a
reading mirror as the lowest concentration of drug that prevents any recogniz-
able growth (100% inhibition) for amphotericin B, itraconazole, voriconazole,
posaconazole, and isavuconazole. For fluconazole, a prominent reduction of
growth (50%) compared to the growth of the drug-free control was used. The
minimum effective concentration (MEC) was defined microscopically as the
lowest concentration of drug that leads to the growth of small, rounded, compact
hyphal forms rather than the long, unbranched hyphal clusters that were seen in
the growth control (9). Paecilomyces variotii (ATCC 22319), Candida parapsilosis
(ATCC 22019), and Candida krusei (ATCC 6258) were used as quality control
organisms. Values for MIC50 and MIC90 were obtained by ordering the MIC
data for each antifungal in ascending arrays and selecting the median and 90th
quartile of the MIC distribution, respectively. Geometric mean MICs were com-
puted using the Microsoft Office Excel 2003 SP3 program, for which purpose
values less than x were set equal to 0.5x.
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RESULTS
Figure 1 depicts a dendrogram of the AFLP analysis with the
type strains of C. bantiana, C. emmonsii, C. devriesi, C. modesta,
and C. arxii demonstrating that C. bantiana is phylogenetically
distinct from the other Cladophialophora spp. The AFLP pat-
terns of C. bantiana strains from different geographical regions
(Table 1), such as the United States, Japan, India, Belgium,
France, South Africa, Mexico, and Brazil, clustered together.
The structuring of this data set suggests that C. bantiana pop-
ulations dispersed quickly across the world. There was one
main cluster of C. bantiana, including the type strain (CBS
173.52), with similarities of more than75%. The C. emmonsii
strains segregate in one cluster, including the reference strain
(CBS 979.96) and one clinical taxon originating from a subcu-
taneous lesion, which had 50% similarity to each other. The
remaining taxa from clinical sources were represented by single
strains, and the AFLP pattern shows that they are completely
distinct from the C. bantiana and C. emmonsii clade (20%
similarity).
Table 2 summarizes the results of the geometric mean MICs,
MIC ranges, and MIC50 and MIC90 distributions of eight an-
tifungal agents for 37 C. bantiana isolates. Five other clinical
TABLE 1. Isolation data for the tested Cladophialophora strainsa
Strain CBS strain no. Other strain reference(s) Source Geography
Cladophialophora bantiana CBS 101251 ATCC 58037, CDC B-3112 Human, brain abscess USA
Cladophialophora bantiana CBS 100428 ATCC 22649 Human, brain abscess USA
Cladophialophora bantiana CBS 119547 dH 16810 Human, brain abscess USA, North Carolina
Cladophialophora bantiana CBS 564.82 ATCC 46715, dH 16022 Human, brain abscess USA, Maryland
Cladophialophora bantiana CBS 110013 dH 12086 Human, brain abscess USA, Kentucky
Cladophialophora bantiana CBS 194.54 dH 15506 Human origin, unknown source USA, Pennsylvania
Cladophialophora bantiana CBS 100432 ATCC 58035, CDC B-1551 Human, brain abscess USA, Georgia
Cladophialophora bantiana CBS 173.52 ATCC 10958 CDC B-1940 (T) Human, brain abscess USA
Cladophialophora bantiana CBS 101252 ATCC 58040, CDC B-3466 Human, brain abscess USA, Washington, DC
Cladophialophora bantiana CBS 110009 dH 12082 Human origin, brain abscess USA, North Carolina
Cladophialophora bantiana CBS 110011 dH 12084 Human origin, unknown source USA, West Virginia
Cladophialophora bantiana CBS 110008 dH 12081 Human origin, unknown source USA, Missouri
Cladophialophora bantiana CBS 110010 dH 12083 Human origin, unknown source USA, Virginia
Cladophialophora bantiana CBS 110007 dH 12080 Human, brain abscess USA
Cladophialophora bantiana CBS 644.96 IFM 41438 Human origin, unknown source Japan
Cladophialophora bantiana CBS 101253 IFM 41439, dH 15162 Human origin, unknown source Japan
Cladophialophora bantiana CBS 642.96 IFM 41436, dH 16119 Human origin, unknown source Japan
Cladophialophora bantiana CBS 641.96 IFM 41434, dH 16116 Human origin, unknown source Japan
Cladophialophora bantiana CBS 643.96 IFM 41437, dH 16121 Human origin, unknown source Japan
Cladophialophora bantiana CBS 646.96 IFM 4820, DCU 651 Human origin, unknown source Japan
Cladophialophora bantiana CBS 101158 ATCC 44223, CDC B-3426 Human, brain abscess Japan
Cladophialophora bantiana CBS 100431 ATCC 44217 Human, subcutaneous
phaeohyphomycosis
India
Cladophialophora bantiana CBS 155.53 Human, brain abscess Belgium
Cladophialophora bantiana CBS 102586 dH 11331 Human, brain abscess Brazil
Cladophialophora bantiana CBS 119719 dH 14515 Human, subcutaneous
phaeohyphomycosis
Thailand
Cladophialophora bantiana CBS 100429 ATCC 24928, dH 10739 Human, brain abscess Unknown
Cladophialophora bantiana CBS 123392 dH 16363 Human, eumycetoma Mexico
Cladophialophora bantiana CBS 984.96 SAIMR J-1872 Human, brain abscess South Africa
Cladophialophora bantiana CBS 649.96 SAIMR W262 Human, subcutaneous
phaeohyphomycosis
South Africa
Cladophialophora bantiana CBS 981.96 UAMH 6501, dH 16330 Human, brain abscess Canada, Edmonton
Cladophialophora bantiana CBS 120376 dH 16362 Human, subcutaneous
phaeohyphomycosis leg
Sweden
Cladophialophora bantiana CBS 100436 ATCC 58039, CDC B-1897 Cat, brain abscess USA, California
Cladophialophora bantiana CBS 648.96 UAMH 3830 Dog, liver abscess Canada, Edmonton, Alberta
Cladophialophora bantiana CBS 118738 CNRMA 2004/222 Dog, thorax tumefaction France, Montpellier
Cladophialophora bantiana CBS 444.96 Dog, disseminated infection South Africa
Cladophialophora bantiana CBS 328.65 CDC B-3394, NCMH 1168 Dog, liver abscess Netherlands Antilles
Cladophialophora bantiana CBS 647.96 CDC 3432, IFM 4821 Mouse, experimentally infected
by sawdust
USA
Cladophialophora modesta CBS 985.96 UAMH 4004, dH 16331 (T) Human, brain abscess USA, North Carolina
Cladophialophora emmonsii CBS 979.96 CDC B-3875, NCMH 2247 (T) Human, subcutaneous
phaeohyphomycosis
USA, Virginia
Cladophialophora emmonsii CBS 102594 CDC B-5420, dH 11918 Human, subcutaneous
phaeohyphomycosis, hand
USA, Virginia
Cladophialophora arxii CBS 102461 CDC B-5887, dH 11524 Human, brain abscess USA, Florida
Cladophialophora devriesii CBS 147.84 ATCC 56280, dH 15405 (T) Human, disseminated infection Grand Cayman Islands
a Abbreviations: ATCC, American Type Culture Collection, Manassas, VA; CBS, Centraalbureau voor Schimmelcultures, Utrecht, Netherlands; dH, G. S. de Hoog
working collection, Utrecht, Netherlands; CDC, Centers for Disease Control and Prevention, Atlanta, GA; UAMH, University of Alberta Microfungus Collection and
Herbarium, Edmonton, Alberta, Canada; IFM, Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, Chiba, Japan; SAIMR, South African
Institute for Medical Research, Johannesburg, South Africa; NCMH, North Carolina Memorial Hospital, Chapel Hill, NC; DCU, Department of Dermatology, School
of Medicine, Chiba, Japan; CNRMA, Collection of the National Reference Center for Mycoses and Antifungals at the Pasteur Institute of Paris; (T), ex-type culture.
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Cladophialophora species have individual MIC results similar
to the C. bantiana MIC90 data. For each antifungal, the MIC50
and geometric mean MIC values differed by 1 log2 dilution
step, indicating that in all cases the MIC50s obtained by
inspection reasonably reflect the central tendency of the
antifungal susceptibility of the population. Overall, all of the
isolates showed a uniform pattern of low MICs for itracon-
azole, posaconazole, and isavuconazole. The widest ranges
and the highest MICs were seen for fluconazole (range, 16
to 64 g/ml). Amphotericin B MICs ranged from 0.125 to 2
g/ml; and itraconazole, posaconazole, and isavuconazole
had MIC ranges of 0.016 to 0.25 g/ml, 0.016 to 0.25
g/ml, and 0.008 to 1 g/ml, respectively. There were no dif-
ferences in the activities of itraconazole and posaconazole; and
they were generally more active than amphotericin B, flucon-
azole, voriconazole, and isavuconazole. C. modesta, C. arxii, C.
emmonsii (Xylohypha emmonsii), and C. devriesii were also
inhibited by low concentrations of azoles, similar to C. banti-
ana. Isavuconazole exhibited potent activity against C. banti-
ana and the other neurotropic strains with a MIC90 of 0.5
g/ml. The voriconazole MIC90 (2 g/ml) was 2-log2-dilu-
tion steps less active than isavuconazole (0.5 g/ml), which
in turn was 2-log2-dilution steps less active than itraconazole
and posaconazole (MIC90, 0.125 g/ml). The only available
isolate of C. modesta had a high MIC (2 g/ml) for voricon-
azole and isavuconazole, similar to the MIC90 of voriconazole
for C. bantiana. Of the two echinocandins, anidulafungin had
the best activity, with the geometric mean MEC being 5 log2
dilution steps more active than caspofungin, although the
MEC90 of 2 g/ml would not qualify anidulafungin as an agent
which can be used as monotherapy.
DISCUSSION
Primary cerebral phaeohyphomycosis in humans without ob-
vious predisposing factors is rare, but it is increasingly recog-
nized as an infectious disease associated with high mortality
and a poor prognosis (13, 26, 37, 48). The most common agent
of cerebral phaeohyphomycosis that belongs to the order of
Chaetothyriales is C. bantiana, which has been reported in both
healthy and immunocompromised hosts. In addition, other
species causing similar clinical presentations have been de-
FIG. 1. Dendrogram of AFLP analysis of 42 Cladophialophora isolates (numbers to the right of the figure are CBS strain designations; the scale
bar on the left indicates the percent similarity).
TABLE 2. Geometric mean MICs, MIC ranges, MIC50s, and MIC90s of eight antifungal drugs against 42 strains of Cladophialophora
Drug
MIC (g/ml)
Cladophialophora bantiana (n  37)
C. modesta
(n  1)
C. arxii
(n  1)
C. devriesii
(n  1)
C. emmonsii
(n  2)
Range Geometric mean 50% 90% Strain1
Strain
2
Amphotericin B 0.125–2 0.7 1 1 1 1 2 0.5 1
Fluconazole 16–64 35.14 32 64 32 8 16 32 32
Itraconazole 0.016–0.25 0.064 0.063 0.125 0.5 0.016 0.031 0.125 0.125
Voriconazole 0.125–4 0.769 1 2 2 0.125 0.25 2 0.5
Posaconazole 0.016–0.25 0.044 0.031 0.125 0.25 0.016 0.031 0.063 0.063
Isavuconazole 0.008–1 0.259 0.25 0.5 2 0.063 0.031 1 1
Caspofungina 1–8 2.551 2 4 4 2 2 2 4
Anidulafungina 0.016–4 0.073 0.063 2 0.5 1 1 1 1
a Data for caspofungin and anidulafungin represent MECs (g/ml).
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scribed. Patients with bone marrow and solid organ transplan-
tation and patients who are on steroid therapy are particularly
affected (2, 13, 15, 24, 31, 35, 36, 51, 54, 57). Cladophialophora
bantiana, a neurotropic fungus, has rarely been isolated from
sources other than clinical samples. C. bantiana is distributed
worldwide, but infections with this organism are especially
encountered in subtropical and humid climate areas (8). Al-
though C. bantiana has been recovered from the environment
(12) and clinical infections are linked to traumatic inoculation
(46), the environmental niche of C. bantiana is largely un-
known; and only one such strain of C. bantiana (CBS 647.96),
recovered from sawdust, was available in this study. An unam-
biguous connection between a clinical and an environmental
strain still has to be proven.
Correct identification by mycological procedures remains
difficult, due to the high degree of phenotypic similarity be-
tween these groups of fungi. For most cases published in the
older literature, the etiological agent may often have been
misidentified; however, reidentification down to the species
level cannot be performed by molecular methods due to the
absence of the original isolates. Recently, molecular data have
shown that Cladophialophora contains a number of hitherto
unknown species closely related but significantly different from
C. bantiana (3). A study of the variability and molecular de-
termination of the neurotropic species C. bantiana and se-
quencing data for the internal transcribed sequence indicated
a low degree of variability (20). Interestingly, C. bantiana con-
sistently contains an invariable intron of 558 bp at position
1768 in the small-subunit rDNA gene, while it was absent and
present in all C. emmonsii isolates and C. psammophila, re-
spectively, which are closely related to C. bantiana (3). Re-
markably, this intron might be involved in evolutionary events,
because it is not found outside the genetically homogeneous
species C. bantiana. Other neurotropic species of Cladophialo-
phora closely related to C. bantiana are involved in brain in-
fections. A fatal cerebral infection with Cladophialophora mod-
esta was reported in a 25-year-old black male after possible
traumatic inoculation (40), and Cladophialophora arxii was
found as the cause of cerebral phaeohyphomycosis in a 30-
year-old African-American female who underwent cardiac
transplantation for postpartum cardiomyopathy (44). In con-
trast, Cladophialophora devriesii was involved in a case of dis-
seminated disease without involvement of the central nervous
system (42), which years before presented as subcutaneous
mycosis (22). C. (Xylohypha) emmonsii was the cause of a
subcutaneous mycosis (45), and C. boppii was responsible for a
pulmonary infection in a lung transplant recipient (34).
AFLP is one of a series of techniques for phylogenetic stud-
ies, plant and animal genetic mapping, and genotyping and is
well suited for distinguishing closely related organisms at the
species to strain level (32). The AFLP method relies on
selective amplification of restriction fragments from a digest
of genomic DNA and has many advantages compared to
other marker technologies, including randomly amplified poly-
morphic DNA, restriction fragment length polymorphism, and
microsatellites. AFLP not only has higher reproducibility, res-
olution, and sensitivity at the whole-genome level than other
random amplification techniques but it also has the ability to
amplify between 50 and 100 fragments at one time. In addition,
no prior sequence information is needed for amplification (58).
Bakkeren et al. (5) have shown that the phylogenetic trees
obtained from AFLP analysis are quite similar to those ob-
tained by the use of ITS sequences in Ustilago species and, in
addition, permit distinction of closely related isolates that can-
not be resolved by ITS sequence comparison.
Our AFLP results are in line with previous sequencing data
and also show obvious differences among clinically important
Cladophialophora species as agents of cerebral infection. On
the basis of the AFLP patterns, we did not see any misidenti-
fication for those taxa. All strains in this study were originally
identified as C. bantiana, C. emmonsii, C. arxii, C. devriesii, and
C. modesta on the basis of sequencing and phenotypic and
physiological criteria, which is in the line with the results of
cluster analysis demonstrating a clear separation of C. bantiana
as a rather homogeneous group from C. modesta, C. emmonsii,
C. arxii, and C. devriesii. Although dematiaceous fungi as
agents of central nervous system infections are generally sus-
ceptible to most antifungal agents in vitro, treatment is difficult
because frequent relapses and failures are observed (48). An-
tifungal therapy is based on the experience from single patient
case reports or small series which mostly involved amphoteri-
cin B, itraconazole, and flucytosine. In animal models, ampho-
tericin B prolonged the survival of mice infected with C. ban-
tiana, but the infection did not completely disappear (1).
Although the in vitro activity of amphotericin B against C.
bantiana has been demonstrated in this and previous studies,
the drug was ineffective in many cases of cerebral phaeohy-
phomycosis with or without flucytosine (15, 19, 24, 25, 40, 48,
49, 52). In vitro results indicate that the amphotericin B MICs
for most nondermatophyte opportunistic filamentous fungal
isolates clustered between 0.5 and 2 g/ml. Very few data
concerning the correlation between the MIC and the outcome
of treatment with amphotericin B are available for dematia-
ceous fungi. Generally, filamentous fungi are not susceptible to
fluconazole and most MICs were 16 g/ml. Two case reports
described the improvement of C. bantiana brain abscesses after
treatment with fluconazole for up to 6 weeks and surgical
excision (11, 55). Surgical intervention was probably the cause
of the improvement. Fortunately, the antifungal armamentar-
ium has been extended with new triazoles, potent agents that
are active against drug-resistant strains and that have less tox-
icity. There are only limited data in the literature regarding the
susceptibility of C. bantiana isolates to antifungals (47). Less
successful outcomes of treatment with itraconazole (44) and
voriconazole (17, 24, 49) for cerebral abscesses due to C. ban-
tiana were observed, although itraconazole had low MICs
(MIC90, 0.125 g/ml) in this study. The explanation might be
the less optimal penetration into the CNS. Whereas voricon-
azole has a good penetration into the CNS, the MICs of C.
bantiana were in the higher ranges (MIC90, 2 g/ml). Some
authors report successful treatment of C. bantiana brain ab-
scesses with voriconazole (38), while others reported clinical
failure (17, 24, 49). Although it is an excellent drug for the
treatment of cerebral aspergillosis, voriconazole might not be
the first choice for the treatment of C. bantiana infections. In
contrast to another study with only seven strains of C. bantiana
(47), which gave a MIC range of 0.12 to 1 g/ml of voricon-
azole, we found a large range of activity (MICs, 0.125 to 4
g/ml). Therefore, in vitro susceptibility testing may be war-
ranted before voriconazole is used to treat a CNS infection due
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to C. bantiana. Posaconazole and itraconazole (MIC90, 0.125
g/ml) demonstrated the best in vitro activities, followed by
isavuconazole (MIC90, 0.5 g/ml). Some clinical experience
suggests that therapy with itraconazole was successfully used in
treating a C. bantiana cerebral infection (25, 35), eumycetoma
(7), and C. arxii osteomyelitis (53). Treatment with posacon-
azole is supported by our in vitro results, other in vitro data
from small series (n 5, range 0.06 to 0.5 g/ml) (16), data for
a clinical case (18), and data from murine infection models in
which posaconazole prolonged the survival of mice and re-
duced the level of brain fungal burden compared to that
achieved with itraconazole and amphotericin B (1, 39).
Moreover, the apparently good penetration into the CNS
(50) supports the use of posaconazole for this difficult-to-
treat infection. Most melanized fungi appear to be resistant
to echinocandins, probably due to the reduced presence of
-glucan in the cell walls (16, 43). We found that caspofungin
had poor activity but that anidulafungin had activity against C.
bantiana showing a geometric mean MIC of only 0.073 g/ml,
although several isolates had high MECs (MEC90, 2 g/ml).
Another echinocandin, micafungin, was not active in animal
studies when it was used as monotherapy but seemed to be
promising in combination with posaconazole and flucytosine
(39). The investigational agent isavuconazole shows broad-
spectrum activity against many opportunistic and true patho-
genic fungi (21). Here, we show that isavuconazole is also
active against C. bantiana, but its true value needs to be con-
firmed in animal models.
In conclusion, itraconazole, posaconazole, and isavucon-
azole demonstrated in vitro activity against neurotropic isolates
of C. bantiana. Some positive and negative correlating clinical
experiences are available for itraconazole, voriconazole, and
posaconazole; but the most important intervention for cerebral
phaeohyphomycosis caused by C. bantiana probably remains
complete neurosurgical excision of the abscesses.
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